Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | GLS | O94925 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3235704 | 0.87 | CYP1A2 (0.49) | CTBP2HSP90AB1HSP90AA1 | |
| SCHEMBL4190201 | 0.86 | DRD2 (0.50) | SMN1; SMN2DRD2HSP90AB1POLBHSP90AA1 | |
| SCHEMBL18294034 | 0.85 | AOC2 (0.47) | ALDH1A1HSP90AB1POLBGLSHSP90AA1 | |
| SCHEMBL6362544 | 0.84 | F10 (0.44) | DRD2CTBP2HSP90AB1HSP90AA1 | |
| SCHEMBL1279084 | 0.84 | MEN1 (0.46) | SMN1; SMN2ALDH1A1POLBMAPTHPGD | |
| SCHEMBL14987130 | 0.83 | SLC7A5 (0.41) | SLC7A5SMN1; SMN2ALDH1A1GAAGLS | |
| SCHEMBL3839217 | 0.82 | CYP4F2 (0.50) | SMN1; SMN2DRD2ALDH1A1GAAGFER | |
| SCHEMBL10196989 | 0.82 | F10 (0.44) | DRD2CTBP2HSP90AB1GLSHSP90AA1 | |
| SCHEMBL4183069 | 0.82 | HSP90AB1 (0.61) | SMN1; SMN2DRD2ALDH1A1GAAGFER | |
| SCHEMBL10697163 | 0.81 | HSP90AA1 (0.41) | DRD2ALDH1A1CTBP2HSP90AB1GLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12516055-B2 | Protein kinase inhibitors and uses thereof for the treatment of diseases and conditions | TRUSTEES OF TUFTS COLLEGE (US) | 2026-01-06 | — | — | US | disclosed |
| EP-4480485-A2 | PROTEIN KINASE INHIBITORS AND USES THEREOF FOR THE TREATMENT OF DISEASES AND CONDITIONS | University of Houston System (US) | 2024-12-25 | — | — | EP | disclosed |
| EP-3968991-B1 | PROTEIN KINASE INHIBITORS AND USES THEREOF FOR THE TREATMENT OF DISEASES AND CONDITIONS | UNIV HOUSTON SYSTEM (US) | 2024-07-31 | — | — | EP | disclosed |
| EP-4276092-A1 | COMPOUND LIBRARY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-11-15 | — | — | EP | disclosed |
| EP-4276092-A1 | COMPOUND LIBRARY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-11-15 | — | — | EP | disclosed |
| US-11708347-B2 | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20220194937-A1 | PROTEIN KINASE INHIBITORS AND USES THEREOF FOR THE TREATMENT OF DISEASES AND CONDITIONS | UNIVERSITY OF HOUSTON SYSTEM | 2022-06-23 | — | — | US | disclosed |
| EP-3968991-A1 | PROTEIN KINASE INHIBITORS AND USES THEREOF FOR THE TREATMENT OF DISEASES AND CONDITIONS | University of Houston System (US) | 2022-03-23 | — | — | EP | disclosed |
| WO-2020232190-A1 | PROTEIN KINASE INHIBITORS AND USES THEREOF FOR THE TREATMENT OF DISEASES AND CONDITIONS | UNIVERSITY OF HOUSTON SYSTEM (US) | 2020-11-19 | — | — | WO | disclosed |
| US-5362879-A | 4-5-diphenyloxazole derivatives as inhibitors of blood platelet aggregation | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220194937-A1 | PROTEIN KINASE INHIBITORS AND USES THEREOF FOR THE TREATMENT OF DISEASES AND CONDITIONS | RIPK2, RIPK1, RIPK4 | SLC7A5 4269/4885SMN1; SMN2 1451/4885DRD2 4421/4885 |
| US-11708347-B2 | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors | C9, C5, C1QBP | SLC7A5 2191/4885SMN1; SMN2 2080/4885DRD2 4071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.